UCB's FINTEPLA Shows Rapid Seizure Reduction in Lennox-Gastaut Syndrome Patients — UCB S.A.

Event summary

Post hoc analysis of FINTEPLA in Lennox-Gastaut syndrome (LGS) patients showed rapid seizure frequency reduction and global functioning improvements.
Patients transitioning from placebo to FINTEPLA experienced a -32.1% median reduction in seizures associated with falls within one month.
Safety profile remained consistent, with adverse events decreasing over time with continued treatment.
Study included 151 patients who completed 12 months of FINTEPLA treatment in the open-label extension phase.

The big picture

UCB's findings underscore the critical need for effective treatments in managing Lennox-Gastaut syndrome, a severe and often drug-resistant form of epilepsy. The rapid onset of seizure reduction and sustained improvements in global functioning highlight FINTEPLA's potential to address unmet medical needs in this patient population. As UCB continues to gather long-term data, these results could further solidify FINTEPLA's position as a key therapeutic option for rare epilepsies.

What we're watching

Dose Optimization: How the observed dose-dependent improvements will influence future treatment protocols for LGS patients.
Long-term Safety: Whether the decreasing incidence of adverse events with continued FINTEPLA use will support extended treatment regimens.
Market Positioning: The pace at which UCB can leverage these findings to strengthen FINTEPLA's market share in rare epilepsy treatments.